Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Post-Mkt 09-30 18:01:51 EDT

0.8051

-0.0063

-0.77%

盘后0.7899

-0.0152-1.89%

18:00 EDT

High0.8399	Low0.8001	Vol54.37K
Open0.8145	D1 Closing0.8114	Amplitude4.91%
Mkt Cap2.71M	Tradable Cap2.71M	Total Shares3.37M
T/O44.14K	T/O Rate1.62%	Tradable Shares3.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":0.805115,"timestamp":1790798400000,"preClose":0.8114,"halted":0,"volume":54367,"hourTrading":{"tag":"盘后","latestPrice":0.7899,"preClose":0.805115,"latestTime":"18:00 EDT","volume":12916,"amount":10227.586264,"timestamp":1790805657114,"change":-0.015215,"changeRate":-0.018898,"amplitude":0.070797},"delay":0,"changeRate":-0.00774587133349764,"floatShares":3365700,"shares":3367100,"eps":-14.801314,"marketStatus":"Post-Mkt","change":-0.006285,"latestTime":"09-30 18:01:51 EDT","open":0.8145,"high":0.8399,"low":0.8001,"amount":44142.47395069,"amplitude":0.049051,"askPrice":0.84,"askSize":500,"bidPrice":0.7134,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-14.801314,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790812800000},"marketStatusCode":4,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":0.8114,"preHourTrading":{"tag":"盘前","latestPrice":0.81,"preClose":0.8114,"latestTime":"09:06 EDT","volume":1903,"amount":1556.6068056,"timestamp":1790773598000,"change":-0.0014,"changeRate":-0.001725,"amplitude":0.061622},"postHourTrading":{"tag":"盘后","latestPrice":0.7899,"preClose":0.805115,"latestTime":"18:00 EDT","volume":12916,"amount":10227.586264,"timestamp":1790805657114,"change":-0.015215,"changeRate":-0.018898,"amplitude":0.070797},"volumeRatio":0.431177},"requestUrl":"/m/hq/s/CMND/wiki","defaultTab":"wiki","newsList":[{"id":"2672578208","title":"Clearmind Medicine: Effects 1-for-8 Reverse Share Split, Effective October 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672578208","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672578208?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:36","pubTimestamp":1790800598,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M150:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672822427","title":"Clearmind Medicine to Consolidate Shares 1-for-8 Oct. 5 on NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2672822427","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672822427?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:32","pubTimestamp":1790800367,"startTime":"0","endTime":"0","summary":"Clearmind Medicine to consolidate shares 1-for-8 Oct. 5 on NasdaqClearmind Medicine will execute a 1-for-8 reverse share split of its common shares.Post-split trading on the Nasdaq Capital Market is s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL2jWQky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669485824","title":"NeuroThera Labs Expands U.S. Patent Portfolio in Collaboration with Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2669485824","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669485824?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:16","pubTimestamp":1790165796,"startTime":"0","endTime":"0","summary":"NeuroThera Labs expands U.S. patent portfolio in collaboration with Clearmind MedicineNeuroThera expanded its collaboration with Clearmind Medicine to build U.S. patent coverage for PEA combinations w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL26bDzZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669948368","title":"Clearmind Medicine Publishes Three US Patent Applications for LSD, Ketamine, Ibogaine Combinations with PEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669948368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669948368?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:57","pubTimestamp":1790164637,"startTime":"0","endTime":"0","summary":"Clearmind Medicine publishes three US patent applications for LSD, ketamine, ibogaine combinations with PEAClearmind Medicine published three U.S. patent applications covering combinations of LSD, ket","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL3vM9xg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","BK4112","IE00BQXX3D17.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4007","SG9999014005.SGD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","NDAQ","BK4585","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","LU0314104364.USD","CMND","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668964197","title":"Clearmind Medicine briefs FDA following psychedelic hearing in Washington D.C.","url":"https://stock-news.laohu8.com/highlight/detail?id=2668964197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668964197?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:50","pubTimestamp":1789645810,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced that, following an invitation from the FDA, it testified at the FDA’s psychedelic hearing in the nation’s capit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-briefs-fda-following-psychedelic-hearing-in-washington-d-c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-briefs-fda-following-psychedelic-hearing-in-washington-d-c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMND","LABU","BK4007","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668961272","title":"Clearmind Briefs FDA Panel at Washington Psychedelic Drugs Hearing","url":"https://stock-news.laohu8.com/highlight/detail?id=2668961272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668961272?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:42","pubTimestamp":1789645338,"startTime":"0","endTime":"0","summary":"Clearmind briefs FDA panel at Washington psychedelic drugs hearingClearmind Medicine testified at the FDA’s psychedelic hearing in Washington on Sept. 14, 2026, following an FDA invitation.Mary-Elizab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDLbqryCR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","BK4112","IE00BQXX3D17.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4007","SG9999014005.SGD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","NDAQ","BK4585","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","LU0314104364.USD","CMND","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666217245","title":"Clearmind Enrolls First AUD Patients in CMND-100 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666217245","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666217245?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:02","pubTimestamp":1789128132,"startTime":"0","endTime":"0","summary":"Clearmind enrolls first AUD patients in CMND-100 clinical trialClearmind Medicine enrolled the first Alcohol Use Disorder patients in its CMND-100 clinical trial.Results have not been presented; the s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL4X4j3R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","NDAQ","SG9999014005.SGD","LU2210150020.SGD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","CMND","IE00BQXX3F31.USD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","IE00BN0W2T93.GBP","BK4588","BK4112","SG9999014013.SGD","BK4007","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666652125","title":"Clearmind Enrolls First Patients with Alcohol Use Disorder in Cmnd-100 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666652125","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666652125?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128051,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513797","title":"Clearmind Net Loss Narrows to USD 907,291 in Q3 FY26; Cash Climbs to USD 12.04 Million at July 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513797","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666513797?lang=en_us&edition=fundamental","pubTime":"2026-09-11 04:08","pubTimestamp":1789070927,"startTime":"0","endTime":"0","summary":"Clearmind net loss narrows to USD 907,291 in Q3 FY26; cash climbs to USD 12.04 million at July 31, 2026Clearmind Medicine reported a net loss of USD 907,291 for the three months ended July 31, 2026, n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDLc988vT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327479","title":"Clearmind Medicine Wins Yale IRB Clearance to Recruit Patients for CMND-100 Trial Parts B and C","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327479","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327479?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:42","pubTimestamp":1788867740,"startTime":"0","endTime":"0","summary":"Clearmind Medicine wins Yale IRB clearance to recruit patients for CMND-100 trial parts B and CClearmind Medicine won Yale University IRB clearance to start recruiting patients for Parts B and C of it","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLc3rzPn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","NDAQ","SG9999014021.USD","BK4112","IE00BQXX3F31.USD","BK4585","BK4588","SG9999014039.USD","CMND","BK4007","BCDF","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532747","title":"Clearmind Medicine Receives Yale Irb Approval, Enabling Patient Recruitment for Parts B and C of Cmnd-100 Phase I/Ii Trial, Following Positive Safety Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532747","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532747?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:42","pubTimestamp":1788867720,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA2LKZLZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664339136","title":"Clearmind Medicine Agrees to Buy 51% of Charging Robotics for $2.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664339136?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:32","pubTimestamp":1788521539,"startTime":"0","endTime":"0","summary":"Clearmind Medicine agrees to buy 51% of Charging Robotics for $2.5 millionClearmind Medicine agreed to buy 51% of Charging Robotics for USD 2.5 million.Deal includes a USD 1.5 million loan to Charging","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL97C896:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014021.USD","BK4124","BK4112","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","LU2095319765.USD","NDAQ","BK4588","IE00B64PRP62.GBP","CMND","LU0314104364.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4007","IE00BN0W2T93.GBP","CHEV","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664633918","title":"Clearmind Medicine - to Extend $1.50 Mln Loan to Charging Robotics at 4% Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2664633918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664633918?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:32","pubTimestamp":1788521520,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA6ZKRHH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664339900","title":"Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2664339900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664339900?lang=en_us&edition=fundamental","pubTime":"2026-09-04 19:32","pubTimestamp":1788521520,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA6ZKRHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664849839","title":"Clearmind Medicine Sets USD 1 Conversion Price for USD 696,079.50 in Notes into Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664849839","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664849839?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:03","pubTimestamp":1788379413,"startTime":"0","endTime":"0","summary":"Clearmind Medicine sets USD 1 conversion price for USD 696,079.50 in notes into common sharesClearmind set a $1 per-share conversion price for outstanding convertible notes totaling USD 696,079.50, ov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL58t3nY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855251","title":"Clearmind Medicine Starts Phase IIa CMND-100 Trial in Alcohol Use Disorder Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855251","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855251?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:37","pubTimestamp":1788262637,"startTime":"0","endTime":"0","summary":"Clearmind Medicine starts Phase IIa CMND-100 trial in alcohol use disorder patientsClearmind Medicine launched a Phase IIa stage in its Phase I/IIa trial of CMND-100 for alcohol use disorder.Results h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL3L61qH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BN0W2T93.GBP","BK4007","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","IE00BQXX3F31.USD","BCDF","IE00BKPKM429.USD","CMND","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","NDAQ","LU2095319765.USD","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","BK4112","IE00BQXX3D17.EUR","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664585523","title":"Clearmind Reaches Key Milestone: Cmnd-100 Phase Iia NOW Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled","url":"https://stock-news.laohu8.com/highlight/detail?id=2664585523","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664585523?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:37","pubTimestamp":1788262620,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nTUA1SZQTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661645271","title":"SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2661645271","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661645271?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:20","pubTimestamp":1787577613,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC) announced that its subsidiary, NeuroThera Labs, and Clearmind Medicine (CMND) have published a U.S. patent application covering a n...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-clearmind-publish-u-s-patent-application-for-mdma-pea-combination-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-clearmind-publish-u-s-patent-application-for-mdma-pea-combination-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","USRD","BK4007","CMND","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276551","title":"Clearmind Medicine Says US Publishes MDMA-PEA Patent Application for PTSD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276551","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276551?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:04","pubTimestamp":1787573044,"startTime":"0","endTime":"0","summary":"Clearmind Medicine says US publishes MDMA-PEA patent application for PTSD treatmentClearmind reported U.S. publication of its patent application covering a combination of MDMA and N-acylethanolamines ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL7WjfCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","NDAQ","SG9999014005.SGD","LU2210150020.SGD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","CMND","IE00BQXX3F31.USD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","IE00BN0W2T93.GBP","BK4588","BK4112","SG9999014013.SGD","BK4007","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276308","title":"Clearmind Advances Mdma-N-Acylethanolamines Ip for the Treatment of Ptsd Amid Rising U.S. Federal Support for Psychedelic Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276308?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:03","pubTimestamp":1787572980,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA8NJTTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":0.0387},{"period":"1month","weight":-0.539},{"period":"3month","weight":-0.6472},{"period":"6month","weight":-0.9249},{"period":"1year","weight":-0.998},{"period":"ytd","weight":-0.9552}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.040615},{"month":2,"riseRate":0.25,"avgChangeRate":-0.154491},{"month":3,"riseRate":0,"avgChangeRate":-0.280646},{"month":4,"riseRate":0.25,"avgChangeRate":-0.205941},{"month":5,"riseRate":0.25,"avgChangeRate":-0.137133},{"month":6,"riseRate":0.25,"avgChangeRate":-0.036058},{"month":7,"riseRate":0.25,"avgChangeRate":-0.051574},{"month":8,"riseRate":0.5,"avgChangeRate":-0.029706},{"month":9,"riseRate":0,"avgChangeRate":-0.317473},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.107561},{"month":11,"riseRate":0,"avgChangeRate":-0.304445},{"month":12,"riseRate":0.25,"avgChangeRate":-0.256594}],"exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}